(4S)-4-((1R)-1-(hydroxyamino)-2-(4-(4-trifluoromethoxyphenoxy)phenylsulfonyl)ethyl)-2,2-dimethyl-[1,3]dioxolane

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (4S)-4-((1R)-1-(hydroxyamino)-2-(4-(4-trifluoromethoxyphenoxy)phenylsulfonyl)ethyl)-2,2-dimethyl-[1,3]dioxolane
• 英文别名: N-[(1R)-1-[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]-2-[4-[4-(trifluoromethoxy)phenoxy]phenyl]sulfonylethyl]hydroxylamine
• 化学式: C₂₀H₂₂F₃NO₇S
• 分子量: 477.458
• InChiKey: BAXIIXZCCUBQIC-ZWKOTPCHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  32
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  112
• 氢给体数：
  2
• 氢受体数：
  11

反应信息

• 作为反应物：
  描述：

  2,2,2-三氟乙基甲酸酯 、 (4S)-4-((1R)-1-(hydroxyamino)-2-(4-(4-trifluoromethoxyphenoxy)phenylsulfonyl)ethyl)-2,2-dimethyl-[1,3]dioxolane 以 various solvent(s) 为溶剂， 反应 20.0h， 生成 (1R)-N-[1-((4S)-2,2-dimethyl[1,3]dioxolan-4-yl)-2-(4-(4-trifluorometyhoxyphenoxy)phenylsulfonyl)ethyl]-N-hydroxyformamide
  参考文献：
  名称：

  Phenoxyphenyl Sulfone N-Formylhydroxylamines (Retrohydroxamates) as Potent, Selective, Orally Bioavailable Matrix Metalloproteinase Inhibitors

  摘要：

  A novel series of sulfone N-formylhydroxylamines (retrohydroxamates) have been investigated as matrix metalloproteinases (MMP) inhibitors. The substitution of the ether linkage of ABT-770 (5) with a sulfone group 13a led to a substantial increase in activity against MMP-9 but was accompanied by a loss of selectivity for inhibition of MMP-2 and -9 over MMP-1 and diminished oral exposure. Replacement of the biphenyl P1' substituent with a phenoxyphenyl group provided compounds that are highly selective for inhibition of MMP-2 and -9 over MMP-1. Optimization of the substituent adjacent to the retrohydroxamate center in this series led to the clinical candidate ABT-518 (6), a highly potent, selective, orally bioavailable MMP inhibitor that has been shown to significantly inhibit tumor growth in animal cancer models.

  DOI：

  10.1021/jm0103920
• 作为产物：
  描述：

  (4S)-2,2-dimethyl-4-((E/Z)-2-(4-(4-trifluoromethoxyphenoxy)phenylsulfonyl)ethenyl)-[1,3]dioxolane 在 羟胺 作用下， 以 四氢呋喃 为溶剂， 反应 5.0h， 以69%的产率得到(4S)-4-((1S)-1-(hydroxyamino)-2-((4-(4'-(trifluoromethoxy)phenoxy)phenyl)sulfonyl)ethyl)-2,2-dimethyl-1,3-dioxolane
  参考文献：
  名称：

  Phenoxyphenyl Sulfone N-Formylhydroxylamines (Retrohydroxamates) as Potent, Selective, Orally Bioavailable Matrix Metalloproteinase Inhibitors

  摘要：

  A novel series of sulfone N-formylhydroxylamines (retrohydroxamates) have been investigated as matrix metalloproteinases (MMP) inhibitors. The substitution of the ether linkage of ABT-770 (5) with a sulfone group 13a led to a substantial increase in activity against MMP-9 but was accompanied by a loss of selectivity for inhibition of MMP-2 and -9 over MMP-1 and diminished oral exposure. Replacement of the biphenyl P1' substituent with a phenoxyphenyl group provided compounds that are highly selective for inhibition of MMP-2 and -9 over MMP-1. Optimization of the substituent adjacent to the retrohydroxamate center in this series led to the clinical candidate ABT-518 (6), a highly potent, selective, orally bioavailable MMP inhibitor that has been shown to significantly inhibit tumor growth in animal cancer models.

  DOI：

  10.1021/jm0103920

文献信息

• The Development of a Large-Scale Synthesis of Matrix Metalloproteinase Inhibitor, ABT-518
  作者：Sou-Jen Chang、Dilinie Fernando、Michael Fickes、Ashok K. Gupta、David R. Hill、Todd McDermott、Shyamal Parekh、Zhenping Tian、Steven J. Wittenberger

  DOI：10.1021/op025525l

  日期：2002.5.1

  A process for the preparation of matrix metalloproteinase inhibitor ABT-518 has been developed. Significant improvements have been made to the first generation synthesis and are described here. The new process is very robust and efficient; multikilogram quantities of the title compound have been synthesized for clinical trials. ABT-518 was prepared by this six-step synthetic sequence in 51% overall yield with >99% ee.
• REVERSE HYDROXAMATE INHIBITORS OF MATRIX METALLOPROTEINASES
  申请人：ABBOTT LABORATORIES

  公开号：EP1147101B1

  公开（公告）日：2002-11-20
• Phenoxyphenyl Sulfone <i>N</i>-Formylhydroxylamines (Retrohydroxamates) as Potent, Selective, Orally Bioavailable Matrix Metalloproteinase Inhibitors
  作者：Carol K. Wada、James H. Holms、Michael L. Curtin、Yujia Dai、Alan S. Florjancic、Robert B. Garland、Yan Guo、H. Robin Heyman、Jamie R. Stacey、Douglas H. Steinman、Daniel H. Albert、Jennifer J. Bouska、Ildiko N. Elmore、Carole L. Goodfellow、Patrick A. Marcotte、Paul Tapang、Douglas W. Morgan、Michael R. Michaelides、Steven K. Davidsen

  DOI：10.1021/jm0103920

  日期：2002.1.1

  A novel series of sulfone N-formylhydroxylamines (retrohydroxamates) have been investigated as matrix metalloproteinases (MMP) inhibitors. The substitution of the ether linkage of ABT-770 (5) with a sulfone group 13a led to a substantial increase in activity against MMP-9 but was accompanied by a loss of selectivity for inhibition of MMP-2 and -9 over MMP-1 and diminished oral exposure. Replacement of the biphenyl P1' substituent with a phenoxyphenyl group provided compounds that are highly selective for inhibition of MMP-2 and -9 over MMP-1. Optimization of the substituent adjacent to the retrohydroxamate center in this series led to the clinical candidate ABT-518 (6), a highly potent, selective, orally bioavailable MMP inhibitor that has been shown to significantly inhibit tumor growth in animal cancer models.